MCID: RBS001
MIFTS: 63

Rabies

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 72 49 55 51 40 3 41 14 69
Lyssa 12 49

Characteristics:

Orphanet epidemiological data:

55
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Rabies

MedlinePlus : 40 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to encephalitis and viral encephalitis, and has symptoms including fever, headache and prickling or itching sensation at the site of bite. An important gene associated with Rabies is PML (Promyelocytic Leukemia), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Atovaquone and chloroquine have been mentioned in the context of this disorder. Affiliated tissues include brain or, brain and testes, and related phenotypes are cellular and hematopoietic system

CDC : 3 Rabies is a preventable viral disease of mammals most often transmitted through the bite of a rabid animal. The vast majority of rabies cases reported to the Centers for Disease Control and Prevention (CDC) each year occur in wild animals like raccoons, skunks, bats, and foxes.

Disease Ontology : 12 A viral infectious disease that results_in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted_by bite of an infected animal, or transmitted_by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

Wikipedia : 72 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Related Disease Score Top Affiliating Genes
1 encephalitis 29.6 CCL5 CXCL10 IRF3 TLR3
2 viral encephalitis 29.3 CCL5 CXCL10 MX1
3 japanese encephalitis 28.9 CCL5 CXCL10 STAT1 TLR3
4 acute hemorrhagic leukoencephalitis 11.0
5 zika fever 10.4 CD40LG STAT1
6 axillary adenitis 10.4 CD40LG STAT1
7 colorado tick fever 10.3 ALB CD40LG
8 cork-handlers' disease 10.3 ALB CD40LG
9 plasmodium malariae malaria 10.3 ALB CD40LG
10 parasitic ichthyosporea infectious disease 10.3 CD40LG NCAM1
11 fournier gangrene 10.3 ALB CD40LG
12 rhinosporidiosis 10.3 CD40LG NCAM1
13 microphthalmia with limb anomalies 10.2 MX1 STAT1 STAT2
14 neuronitis 10.2
15 coccidioidomycosis 10.2 CD40LG STAT1
16 encephalitozoonosis 10.2 CD40LG MX1
17 mumps 10.2 CD40LG STAT1 STAT2
18 intestinal perforation 10.2 NCAM1 NFKB1
19 mouth disease 10.2 IRF3 MX1 STAT1
20 west nile virus 10.2 IRF3 MX1 TLR3
21 yellow nail syndrome 10.2 ALB CD40LG
22 hepatitis e 10.2 ALB CD40LG TLR3
23 aleutian mink disease 10.1 ALB CD40LG NGFR
24 myeloma, multiple 10.1 ALB CD40LG NCAM1
25 tick-borne encephalitis 10.1 ALB CXCL10 TLR3
26 viral hepatitis 10.0 ALB CD40LG MX1
27 measles 10.0 CD40LG STAT1 STAT2 TLR3
28 aging 10.0
29 dengue hemorrhagic fever 10.0 ALB CD40LG STAT1 STAT2
30 japanese spotted fever 10.0 CD40LG CXCL10
31 acrodermatitis 10.0 ALB CXCL10
32 primary bacterial infectious disease 9.9 ALB CD40LG CXCL10
33 blood group, i system 9.9
34 polyarteritis nodosa, childhood-onset 9.9
35 hepatitis c 9.9 CXCL10 IRF3 STAT1 TLR3
36 african tick-bite fever 9.9 CCL5 CD40LG
37 polykaryocytosis inducer 9.9
38 tetanus 9.9
39 vaccinia 9.9
40 transmitted_by 9.9
41 diffuse glomerulonephritis 9.8 ALB CD40LG
42 asymptomatic neurosyphilis 9.8 CD40LG CXCL10
43 neuroblastoma 9.8
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
45 malaria 9.8
46 erythema multiforme 9.8
47 eastern equine encephalitis 9.8
48 st. louis encephalitis 9.8
49 psychotic disorder 9.8
50 newcastle disease 9.8

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Symptoms:

12
  • fever
  • headache
  • prickling or itching sensation at the site of bite
  • anxiety
  • confusion
  • agitation
  • delirium
  • difficulty swallowing
  • hydrophobia
  • paralysis

Human phenotypes related to Rabies:

55 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hallucinations 55 31 hallmark (90%) Very frequent (99-80%) HP:0000738
2 anxiety 55 31 hallmark (90%) Very frequent (99-80%) HP:0000739
3 seizures 55 31 occasional (7.5%) Occasional (29-5%) HP:0001250
4 sudden cardiac death 55 31 occasional (7.5%) Occasional (29-5%) HP:0001645
5 fever 55 31 hallmark (90%) Very frequent (99-80%) HP:0001945
6 diarrhea 55 31 hallmark (90%) Very frequent (99-80%) HP:0002014
7 nausea and vomiting 55 31 hallmark (90%) Very frequent (99-80%) HP:0002017
8 anorexia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002039
9 migraine 55 31 hallmark (90%) Very frequent (99-80%) HP:0002076
10 paresthesia 55 31 hallmark (90%) Very frequent (99-80%) HP:0003401
11 excessive salivation 55 31 hallmark (90%) Very frequent (99-80%) HP:0003781
12 reduced consciousness/confusion 55 31 occasional (7.5%) Occasional (29-5%) HP:0004372
13 attention deficit hyperactivity disorder 55 31 hallmark (90%) Very frequent (99-80%) HP:0007018
14 cerebral palsy 55 31 frequent (33%) Frequent (79-30%) HP:0100021
15 recurrent pharyngitis 55 31 hallmark (90%) Very frequent (99-80%) HP:0100776
16 insomnia 55 31 hallmark (90%) Very frequent (99-80%) HP:0100785
17 vocal cord paresis 55 31 hallmark (90%) Very frequent (99-80%) HP:0001604
18 depression 55 Very frequent (99-80%)
19 behavioral abnormality 55 Very frequent (99-80%)
20 depressivity 31 hallmark (90%) HP:0000716

UMLS symptoms related to Rabies:


pruritus, fever

MGI Mouse Phenotypes related to Rabies:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 NGFR ALB PML CD40LG STAT1 CXCL10
2 hematopoietic system MP:0005397 9.85 NGFR CCL5 PML CD40LG STAT1 CXCL10
3 immune system MP:0005387 9.73 NGFR PML CCL5 CD40LG STAT1 CXCL10
4 mortality/aging MP:0010768 9.36 NFKB1 NGFR ALB PML CD40LG STAT1

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atovaquone Approved Phase 4 95233-18-4 74989
2
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
3
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
4
Proguanil Approved Phase 4 500-92-5 4923
5 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
6 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
7 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
8 gamma-Globulins Phase 4,Phase 2,Phase 3,Phase 1
9 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 3,Phase 1
10 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 3,Phase 1
11 Antibodies, Blocking Phase 4,Phase 2
12 Anti-Bacterial Agents Phase 4,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Antimetabolites Phase 4,Phase 2
15 Antirheumatic Agents Phase 4,Phase 2
16 Analgesics Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Anthelmintics Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21 Antimalarials Phase 4,Phase 3
22 Antiparasitic Agents Phase 4,Phase 3
23 Antiprotozoal Agents Phase 4,Phase 3
24 Atovaquone, proguanil drug combination Phase 4
25 Chloroquine diphosphate Phase 4 50-63-5
26 Peripheral Nervous System Agents Phase 4
27
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
28
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
29
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
30
Lactitol Investigational Phase 3 585-86-4 3871
31 Cathartics Phase 3
32 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
33 Laxatives Phase 3
34 Complement C3 Phase 3
35 Renal Agents Phase 3
36
Aluminum hydroxide Approved, Investigational Phase 2,Phase 1 21645-51-2
37
Abacavir Approved, Investigational Phase 2 136470-78-5 441300 65140
38
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
39
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Zidovudine Approved Phase 2 30516-87-1 35370
42 Antibodies, Monoclonal Phase 2
43
QS 21 Phase 2,Phase 1 141256-04-4
44 Adjuvants, Immunologic Phase 2,Phase 1
45 Antacids Phase 2,Phase 1
46 Anti-Ulcer Agents Phase 2,Phase 1
47 Antifungal Agents Phase 2
48 Anti-HIV Agents Phase 2
49 Anti-Retroviral Agents Phase 2
50 Antiviral Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 101)

# Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With PID Unknown status NCT02490956 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 Rabies Immune Plasma Booster Study Completed NCT01063140 Phase 4
5 Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules Completed NCT01365494 Phase 4
6 Immunogenicity of Rabies Vaccine for Pre Exposure Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
7 A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children Completed NCT02991872 Phase 4
8 Immunogenicity and Safety of Verorab™ in Indian Population Completed NCT00260351 Phase 4
9 The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
10 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
11 Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG Recruiting NCT01137045 Phase 4
12 A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children Withdrawn NCT03192371 Phase 4
13 Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
14 An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial Unknown status NCT00872963 Phase 2, Phase 3
15 Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age Completed NCT02177032 Phase 3
16 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
17 A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Completed NCT02491541 Phase 3
18 Early Rabies Vaccine Immunization in Primary School Children Completed NCT01107275 Phase 3
19 Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine Completed NCT01339312 Phase 3
20 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
21 Purified Rabies Vaccine for Human Use (Chick-embryo Cell) Completed NCT00345319 Phase 3
22 A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults Completed NCT01680016 Phase 3
23 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans Completed NCT02288286 Phase 3
24 Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) Completed NCT00825305 Phase 3
25 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
26 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
27 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Completed NCT00866619 Phase 3
28 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Recruiting NCT02912845 Phase 3 KamRAB - HRIG
29 Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
30 A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. Active, not recruiting NCT02545517 Phase 3
31 Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects Active, not recruiting NCT03264157 Phase 2, Phase 3 HRIG
32 Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen Active, not recruiting NCT01622062 Phase 3
33 Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen Terminated NCT01067079 Phase 3
34 One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding Unknown status NCT02276625 Phase 2
35 Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine Unknown status NCT00652275 Phase 2
36 Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
37 Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen Completed NCT01877395 Phase 2
38 Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen Completed NCT01930357 Phase 2
39 Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use Completed NCT01784874 Phase 2
40 A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines Completed NCT02956746 Phase 1, Phase 2
41 Immunogenicity and Safety of a Purified Vero Rabies Vaccine Completed NCT03145766 Phase 2
42 Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults Completed NCT01228383 Phase 2
43 Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults Completed NCT00948272 Phase 2
44 Rabies Immunization Concomitant With JEV in Children Completed NCT00703521 Phase 2
45 Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents Completed NCT00708084 Phase 2
46 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
47 A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
48 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers Completed NCT00694460 Phase 2
49 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali Completed NCT00460525 Phase 2
50 Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine Completed NCT00223990 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

The Foundational Model of Anatomy Ontology organs/tissues related to Rabies:

18
Brain Or

MalaCards organs/tissues related to Rabies:

38
Brain, Testes, Spinal Cord, Bone Marrow, Liver, Bone, Skin

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 761)
# Title Authors Year
1
Rabies risk and use of post-exposure prophylaxis associated with dog bites in Tennessee. ( 29430859 )
2018
2
Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin. ( 29420464 )
2018
3
Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine. ( 29416659 )
2018
4
Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses. ( 29300155 )
2018
5
Notes from the Field: Assessment of Rabies Exposure Risk Among Residents of a University Sorority House - Indiana, February 2017. ( 29420465 )
2018
6
Qualitative Evaluation of the Five-Year 'Red Collar' Campaign to End Inhumane Culling of Dogs as a Method of Rabies Control. ( 29415427 )
2018
7
Defining objective clusters for rabies virus sequences using affinity propagation clustering. ( 29357361 )
2018
8
Genome Sequence of a Rabies Virus Isolated from a Dog in Chiapas, Mexico, 2013. ( 29371371 )
2018
9
Production of Recombinant Rabies Virus Glycoprotein by Insect Cells in a Single-Use Fixed-Bed Bioreactor. ( 28921430 )
2018
10
MALT1 controls attenuated rabies virus by inducing early inflammation and T cell activation in the brain. ( 29367251 )
2018
11
Development of a genotype-by-sequencing immunogenetic assay as exemplified by screening for variation in red fox with and without endemic rabies exposure. ( 29321894 )
2018
12
An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species. ( 29325820 )
2018
13
Barriers of attendance to dog rabies static point vaccination clinics in Blantyre, Malawi. ( 29324737 )
2018
14
In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines. ( 29439868 )
2018
15
First case of Stevens-Johnson syndrome after rabies vaccination. ( 29333656 )
2018
16
Introduction and Establishment of Raccoon Rabies on Islands: Jekyll Island, Georgia as a Case Study. ( 29369728 )
2018
17
Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine. ( 29328884 )
2018
18
Characterization of rabies post-exposure prophylaxis in a region of the eastern Amazon, state of ParA!, Brazil, between 2000 and 2014. ( 29424092 )
2018
19
Immunological Effect of aGV Rabies Vaccine Administered Using the Essen and Zagreb Regimens: A Double-Blind, Randomized Clinical Trial. ( 29394147 )
2018
20
A Pan-Lyssavirus Taqman Real-Time RT-PCR Assay for the Detection of Highly Variable Rabies virus and Other Lyssaviruses. ( 28081126 )
2017
21
A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. ( 28436708 )
2017
22
Comprehensive Monosynaptic Rabies Virus Mapping of Host Connectivity with Neural Progenitor Grafts after Spinal Cord Injury. ( 28479302 )
2017
23
Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses. ( 28447192 )
2017
24
Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. ( 28514853 )
2017
25
Identification of two classes of somatosensory neurons that display resistance to retrograde infection by rabies virus. ( 28951448 )
2017
26
Effect of counselling on health-care-seeking behaviours and rabies vaccination adherence after dog bites in Haiti, 2014-15: a retrospective follow-up survey. ( 28911750 )
2017
27
Assessing the Risk of a Canine Rabies Incursion in Northern Australia. ( 28913341 )
2017
28
Regulation of NF-I_B by the p105-ABIN2-TPL2 complex and RelAp43 during rabies virus infection. ( 29084252 )
2017
29
Resurgence of rabies in Hungary during 2013-2014: An attempt to track the origin of identified strains. ( 28497505 )
2017
30
The Middle East and Eastern Europe rabies Expert Bureau (MEEREB) third meeting: Lyon-France (7-8 April, 2015). ( 28476258 )
2017
31
Editorial: Towards Elimination of Dog Mediated Human Rabies. ( 28913342 )
2017
32
Rabies Vaccination Targets for Stray Dog Populations. ( 28451589 )
2017
33
Investigating the effect of carbon source on rabies virus glycoprotein production in Pichia pastoris by a transcriptomic approach. ( 28523730 )
2017
34
The Ilocos Norte Communities against Rabies Exposure Elimination Project in the Philippines: Epidemiological and Economic Aspects. ( 28484703 )
2017
35
Rabies screen reveals GPe control of cocaine-triggered plasticity. ( 28902833 )
2017
36
Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study. ( 28931127 )
2017
37
Substantial reductions in rabies, but still a lot to be done. ( 28911756 )
2017
38
Development of molecular confirmation tools for swift and easy rabies diagnostics. ( 28938887 )
2017
39
Lab-Attenuated Rabies Virus Causes Abortive Infection and Induces Cytokine Expression in Astrocytes by Activating Mitochondrial Antiviral-Signaling Protein Signaling Pathway. ( 29403485 )
2017
40
Monosynaptic Tracing in Developing Circuits Using Modified Rabies Virus. ( 27943201 )
2017
41
Risk assessment of the entry of canine-rabies into Papua New Guinea via sea and land routes. ( 28903875 )
2017
42
Susceptibility of neuroblastoma cells to rabies virus may be affected by passage number. ( 28506631 )
2017
43
Rabies: A Novel Clinical Presentation. ( 29307972 )
2017
44
A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector. ( 28899628 )
2017
45
Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine? ( 28065475 )
2017
46
Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. ( 28081969 )
2017
47
Re-emergence of rabies virus maintained by canid populations in Paraguay. ( 28913904 )
2017
48
Rabies Tracing of Birthdated Dentate Granule Cells in Rat Temporal Lobe Epilepsy. ( 28470680 )
2017
49
Multi-Patient Rabies Exposure on a Colorado River Rafting Expedition: Urgent vs. Emergent Transport Decision Making in an Austere Setting. ( 28952816 )
2017
50
Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines. ( 28953450 )
2017

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CCL5 CD40LG CXCL10 IFNA4 IKBKE IRF3
2
Show member pathways
13.74 CCL5 CD40LG CXCL10 MAP3K8 NFKB1 NGFR
3
Show member pathways
13.46 CCL5 IFNA4 IKBKE MAP3K8 NFKB1 NGFR
4
Show member pathways
13.34 CCL5 CD40LG CXCL10 IKBKE MAP3K8 NFKB1
5
Show member pathways
13.21 CCL5 CD40LG CXCL10 IKBKE NFKB1 NGFR
6
Show member pathways
13.15 CCL5 CD40LG CXCL10 IFNA4 IRF3 MAP3K8
7
Show member pathways
13.13 IKBKE MAP3K8 NFKB1 STAT1 STAT2 TLR3
8
Show member pathways
12.94 CCL5 IFNA4 IKBKE IRF3 NFKB1 STAT1
9
Show member pathways
12.84 IFNA4 IKBKE IRF3 MX1 NFKB1 NGFR
10
Show member pathways
12.81 CCL5 CXCL10 NFKB1 STAT1 STAT2
11
Show member pathways
12.81 CCL5 IKBKE MAP3K8 NFKB1 NGFR
12 12.78 IFNA4 NFKB1 PML STAT1 STAT2
13
Show member pathways
12.75 IKBKE IRF3 MAP3K8 NFKB1 NGFR
14
Show member pathways
12.67 CCL5 CXCL10 IFNA4 IKBKE IRF3 NFKB1
15
Show member pathways
12.63 CD40LG IKBKE NFKB1 NGFR TLR3
16
Show member pathways
12.62 CD40LG IKBKE MAP3K8 NFKB1 PML STAT1
17
Show member pathways
12.57 CD40LG IKBKE IRF3 NFKB1 NGFR TLR3
18
Show member pathways
12.52 IFNA4 IKBKE IRF3 NFKB1 STAT1 STAT2
19
Show member pathways
12.44 IFNA4 IRF3 MX1 NCAM1 PML STAT1
20
Show member pathways
12.3 CCL5 CXCL10 IFNA4 IKBKE IRF3 MAP3K8
21
Show member pathways
12.28 IKBKE NFKB1 STAT1 STAT2
22
Show member pathways
12.24 IFNA4 NFKB1 STAT1 STAT2
23
Show member pathways
12.23 IKBKE IRF3 NFKB1 STAT1 TLR3
24
Show member pathways
12.2 IKBKE IRF3 NFKB1 TLR3
25 12.17 CCL5 CD40LG CXCL10 IKBKE IRF3 NCAM1
26
Show member pathways
12.15 IFNA4 STAT1 STAT2 TLR3
27
Show member pathways
12.13 IFNA4 IRF3 MX1 STAT1 STAT2
28 12.06 NCAM1 NFKB1 NGFR STAT1
29
Show member pathways
12.06 CCL5 CXCL10 IFNA4 IKBKE IRF3 MX1
30 11.98 ALB NCAM1 NGFR
31 11.98 IFNA4 IKBKE IRF3 NFKB1 STAT1 STAT2
32 11.96 NFKB1 STAT1 STAT2
33
Show member pathways
11.95 NFKB1 STAT1 TLR3
34 11.91 CCL5 CXCL10 MAP3K8 NFKB1
35
Show member pathways
11.86 STAT1 STAT2 TLR3
36 11.8 IFNA4 IKBKE STAT1 STAT2
37
Show member pathways
11.69 CD40LG NFKB1 NGFR
38 11.66 IKBKE MAP3K8 NFKB1
39 11.33 CXCL10 STAT1 STAT2
40
Show member pathways
11.14 IRF3 MX1 STAT1 STAT2

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 ALB CCL5 CD40LG CXCL10 IFNA4 NCAM1

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 IRF3 MX1 NFKB1 NGFR PML STAT1
2 immune system process GO:0002376 9.97 IRF3 MAP3K8 MX1 PML TLR3
3 immune response GO:0006955 9.97 CCL5 CD40LG CXCL10 IKBKE NGFR
4 viral process GO:0016032 9.93 IRF3 NCAM1 PML STAT1 STAT2
5 innate immune response GO:0045087 9.87 IFNA4 IKBKE IRF3 MX1 NFKB1 PML
6 inflammatory response GO:0006954 9.85 CCL5 CD40LG CXCL10 NFKB1 NGFR TLR3
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.83 CD40LG NGFR STAT1
8 cellular response to lipopolysaccharide GO:0071222 9.83 CXCL10 IRF3 NFKB1
9 negative regulation of angiogenesis GO:0016525 9.8 CXCL10 PML STAT1
10 defense response GO:0006952 9.8 CXCL10 IFNA4 MX1 TLR3
11 cellular response to interferon-gamma GO:0071346 9.78 CCL5 STAT1 TLR3
12 response to cytokine GO:0034097 9.72 CCL5 PML STAT1
13 interferon-gamma-mediated signaling pathway GO:0060333 9.71 IRF3 NCAM1 PML STAT1
14 positive regulation of type I interferon production GO:0032481 9.7 IRF3 NFKB1 TLR3
15 membrane protein intracellular domain proteolysis GO:0031293 9.65 NFKB1 NGFR
16 response to exogenous dsRNA GO:0043330 9.65 IFNA4 IRF3 TLR3
17 positive regulation of monocyte chemotaxis GO:0090026 9.64 CCL5 CXCL10
18 cellular response to interferon-beta GO:0035458 9.64 STAT1 TLR3
19 positive regulation of T cell migration GO:2000406 9.63 CCL5 CXCL10
20 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.63 IKBKE IRF3 TLR3
21 I-kappaB phosphorylation GO:0007252 9.62 IKBKE TLR3
22 positive regulation of interferon-alpha production GO:0032727 9.61 IRF3 STAT1
23 regulation of type I interferon-mediated signaling pathway GO:0060338 9.61 IFNA4 STAT1 STAT2
24 positive regulation of lipid storage GO:0010884 9.6 IKBKE NFKB1
25 response to interferon-beta GO:0035456 9.58 IKBKE STAT1
26 response to type I interferon GO:0034340 9.56 IKBKE MX1
27 response to virus GO:0009615 9.55 CCL5 CXCL10 IFNA4 MX1 TLR3
28 cellular response to dsRNA GO:0071359 9.43 IRF3 NFKB1 TLR3
29 type I interferon signaling pathway GO:0060337 9.35 IFNA4 IRF3 MX1 STAT1 STAT2
30 defense response to virus GO:0051607 9.23 CXCL10 IFNA4 IRF3 MX1 PML STAT1
31 signal transduction GO:0007165 10.19 CXCL10 MAP3K8 MX1 NFKB1 NGFR STAT1
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 CXCL10 IRF3 NFKB1 PML STAT1 TLR3

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 ALB CCL5 CD40LG CXCL10 IFNA4 IKBKE
2 cytokine activity GO:0005125 9.56 CCL5 CD40LG CXCL10 IFNA4
3 ubiquitin-like protein ligase binding GO:0044389 9.32 STAT1 STAT2
4 identical protein binding GO:0042802 9.23 ALB CCL5 IRF3 MX1 NFKB1 STAT1
5 CCR5 chemokine receptor binding GO:0031730 9.16 CCL5 STAT1

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....